PRS24 THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND
Walczak J, Nogas G, Dybek-Karpiuk A, Augustynska J, Stelmachowski J, Garbacka M, Obrzut G, Pawlik D Arcana Institute, Cracow, Poland OBJECTIVES: The aim of the analysis was to estimate the costs and effectiveness of varenicline versus existing smoking cessation strategies in Poland. METHODS: A Markov model, the Benefits of Smoking Cessation on Outcomes (BENESCO) constructed in MS Excel ® was used in the analysis. The smoking cessation strategies were varenicline, bupropion, nicotine replacement therapy (NRT), unaided cessation and placebo. The target population consisted off adult smokers and the time horizon in the model was lifelong. The analysis was performed from both payers' perspective (National Heath Fund and patient). The costs and benefits were discounted at 5% and 3.5% annual rate respectively. The utilities for the included smoking related disease were sourced from the published literature. The quality adjusted life-years (QALY), life years gained (LYG), additional smoking cessation case and additional avoidance of chronic obstructive lung disease (COPD) were used to estimate effectiveness of treatment strategies. A probabilistic and univariate sensitivity analysis was performed to estimate variability of the obtained results relative to used data. RESULTS: Cost of gaining one additional QALY using varenicline versus bupropion, NRT, unaided cessation or placebo was respectively 8,750 PLN; 6, 140 PLN; 8, 827 PLN and 14, 130 PLN. Cost of receiving one additional LYG using varenicline versus bupropion, NRT, unaided cessation or placebo was 12,360 PLN; 8, 673 PLN; 12, 469 PLN and 19, 961 PLN. Cost of one additional smoking cessation case using varenicline versus existing smoking cessation strategies was 6,260 PLN to 10,247 PLN and costs of one avoidance of COPD case was 27 PLN to 62 PLN. CONCLUSIONS: Results of the analysis indicate that varenicline is more effective and more expensive than alternative options for smoking cessation. Incremental cost-effectiveness ratios are below the acceptable threshold, therefore the varenicline can be considered as highly cost-effective treatment.
PRS25 CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR PATIENTS WITH CHRONIC RESPIRATORY DISORDER?
Maunoury To estimate the cost-effectiveness impact of the French gatekeeping system on chronic patient treated with inhaled corticosteroids (ICS). The study question is: Can an incentive economic system as the French gatekeeping ("coordinated care pathway"-CCP, August 2004 French Health Insurance reform) have a significant cost-effectiveness impact, from the Health care system perspective. METHODS: A A retrospective Health insurance database comparative study was performed. A total of 290 patients in each group were included (e.g. the totality of the non-gatekeeping group available in the database), men and women, from 16 to 50 years old, treated with ICS over a minima period of three consecutive months. The propensity score method (PS) was used in order to reduce selection bias from 12 covariates and a semi-Markovian decision model was performed for comparing costs and effectiveness results between treated group and baseline group, based on these matched individuals.
RESULTS:
The semi-Markovian model, based on these groups matched, estimates on
The semi-Markovian model, based on these groups matched, estimates on one-year horizon a 10,000 bootstrap incremental cost-effectiveness ratio (ICER) equal to a33,579 (CI95%: [a33,197; a33,960] ) per QALY gained. This result is a relevant decisional criterion which is lower than the thresholds (1 to 3 GDP per capita) recommended by the World Health Organization ($200023,927 to $200071,781 for the European Economic Community, region A). CONCLUSIONS: This retrospective study This retrospective study on annual observational data has shown that the French gatekeeping system is costeffective in the management of patients with chronic respiratory disorder, from the health care system perspective.
PRS26 COST-EFFECTIVENESS OF GRAZAX IN THE PAEDIATRIC POPULATION FOR THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS IN GERMANY
Whitehead SJ 1 , Taylor MJ 1 , Bech PG 2 , Prenzler A 3 1 University of York, York, UK, 2 ALK-Abelló, Hørsholm, Denmark, 3 Leibniz University of Hannover, Hannover, Germany OBJECTIVES: To evaluate the cost-effectiveness of a grass allergen immunotherapy tablet, Grazax (ALK-Abelló A/S) in combination with symptomatic medications compared to the standard care of symptomatic medications alone for the treatment of grass pollen induced rhinoconjunctivitis. The analysis focuses on children, either with or without co-existing asthma, for the German setting. METHODS: The two treatment options were evaluated in terms of costs and health outcomes using a decision tree approach. The analysis was undertaken from the payer's perspective, with only direct costs included in the base case. The model followed a cohort of 1000 hypothetical children over nine years in the reference case. Continuous use of Grazax was modelled, with the effects of treatment captured in terms of symptom management, resource utilisation and allergic asthma development. Data inputs were drawn from published studies, databases and published clinical trials. RESULTS: The use of Grazax plus symptomatic medications compared to standard care showed an improvement in patient outcomes; 6.92 QALYs as opposed to 6.82 QALYs over the nine-year time horizon. The total cost per patient treated with Grazax was a4117 compared to a1,502 for standard care. The resulting incremental cost per QALY is a25,900. The QALY gains are a result of increased quality of life related to effective symptom management and the reduction in allergic asthma development. Sensitivity analysis carried out around key parameters shows that the results estimated by the model remain robust. CONCLUSIONS: The analysis found Grazax treatment to have an incremental cost per QALY which falls below commonly accepted willingness to pay thresholds. Therefore, Grazax is a cost-effective option for the treatment of grass pollen induced rhinoconjunctivitis for children in Germany.
PRS27 MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD IN GERMANY
Menn P, Holle R Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany OBJECTIVES: To develop a Markov model for health-economic evaluations of COPD in Germany that allows estimating the cost-effectiveness of interventions, and to demonstrate the applicability of the model by evaluating a smoking cessation program compared with usual care. METHODS: A seven-stage Markov model (disease stages I to IV according to GOLD classification, post-surgery, post-transplantation and death) was developed to conduct a cost-utility analysis from the societal perspective with a time horizon of 60 years. Exacerbations were subclassified into mild, moderate and severe. Stage-specific probabilities (for smokers and ex-smokers), utilities and costs were estimated based on German data where possible. Uni-and multivariate as well as probabilistic sensitivity analyses were conducted to assess the robustness of the results. A discount rate of 3% was applied to costs and effects. RESULTS: The smoking cessation program was the dominant strategy compared with usual care, as it resulted in an increase in health effects of 0.5 QALYs and a cost reduction of a1000. Sensitivity analyses showed that uncertainty associated with the model result was mostly due to the lack of evidence for costs in early disease stages. CONCLUSIONS: The model allows estimating the long-term cost-effectiveness of interventions for COPD from a societal perspective in Germany. The smoking cessation program evaluated exemplarily was more effective than usual care as well as cost-saving. Although the majority of patients suffer from mild or moderate COPD, data on resource use in Germany are lacking for these early stages. These data are needed to assess the societal burden of the disease and the cost-effectiveness of interventions. Ospedale Orlandi, Bussolengo, Verona, Italy, 2 AdRes HE&OR, Torino, Italy OBJECTIVES: Omalizumab is an innovative treatment for difficult-to-treat allergic Omalizumab is an innovative treatment for difficult-to-treat allergic asthma. The mechanism of action of this type of treatment relies on impeding the binding of IgEs to their cellular receptor, thus blocking the inflammatory cascade. Objective of this study is to assess real-world clinical and economical outcomes associated to add-on omalizumab in difficult-to-treat allergic asthmatics. METHODS: In the In the
